Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Resproly
company
About
Resproly is a respiratory system inhalation therapy and device developer.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- ¥50M
- Industries
- Biopharma,Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2018
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Resproly is a research and development, production and sales of formula and equipment for respiratory inhalation. An integrated enterprise that focuses on multiple clinically demanding treatment areas such as Asthma, Chronic Obstructive Pulmonary Disease (COPD), Diabetes, and Parkinson's Disease.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
¥50M
Resproly has raised a total of
¥50M
in funding over 2 rounds. Their latest funding was raised on
Aug 29, 2019 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 29, 2019 | Series A | ¥50M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Resproly is funded by 2 investors.
Shenzhen Yanghe Biopharmaceutical Industry Investment
and Huaige Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series A |
Huaige Capital
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
